
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna is viewed favorably because its lead oral PTH1R agonist SEP-479 has shown a ~3-4 day half-life, a safety profile that appears structurally distinct from discontinued SEP-786, and Phase 1 SAD/MAD data in healthy volunteers remains on track for 1Q27, which could de-risk a large hypoparathyroidism opportunity. The company also has multiple additional shots on goal, including SEP-204 for Graves’ disease/TED and SEP-631 for mast-cell driven diseases, both supported by encouraging preclinical or early clinical data and the potential for meaningful platform validation across endocrinology and immunology. Financially, Septerna ended the quarter with $565.2MM in cash and cash equivalents, with runway into 2029 and meaningful R&D support from the Novo Nordisk partnership, while reported losses were narrower than expected.
Bears say
Septerna is a clinical-stage biotechnology company with no approved products, so its value depends heavily on uncertain trial outcomes, regulatory clearance, and eventual commercial adoption across endocrinology, immunology and inflammation, and metabolic disease. The disclosed Phase 1 safety issue in SEP-786, including two unanticipated severe Grade 3 unconjugated bilirubin events that forced dosing discontinuation, highlights platform risk and suggests the company may face further delays, added development costs, or setbacks in future programs such as SEP-631 and other pipeline assets. It also faces significant competitive and commercial pressure, while the risk of a dilutive equity offering could further weaken shareholder returns if funding needs rise before meaningful clinical progress is achieved.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Septerna Inc (SEPN) Forecast
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares